(Q35595402)

9 August 2017

1 reference

title

Resistance to imatinib (Glivec): update on clinical mechanisms (English)

1 reference

9 August 2017

1 reference

Ellen Weisberg

1

1 reference

9 August 2017

James D Griffin

series ordinal

2

1 reference

9 August 2017

publication date

1 October 2003

1 reference

9 August 2017

published in

Drug Resistance Updates

1 reference

9 August 2017

volume

6

1 reference

9 August 2017

issue

5

1 reference

9 August 2017

page(s)

231-238

1 reference

Mechanisms of autoinhibition and STI-571/imatinib resistance revealed by mutagenesis of BCR-ABL.

9 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS1368-7646%2803%2900062-1

7 January 2021

Roots of clinical resistance to STI-571 cancer therapy

1 reference

https://api.crossref.org/works/10.1016%2FS1368-7646%2803%2900062-1

7 January 2021

Mutation in the ATP-binding site of BCR-ABL in a patient with chronic myeloid leukaemia with increasing resistance to STI571.

1 reference

https://api.crossref.org/works/10.1016%2FS1368-7646%2803%2900062-1

7 January 2021

Persistence of malignant hematopoietic progenitors in chronic myelogenous leukemia patients in complete cytogenetic remission following imatinib mesylate treatment

1 reference

https://api.crossref.org/works/10.1016%2FS1368-7646%2803%2900062-1

7 January 2021

Monitoring chronic myeloid leukaemia therapy by real-time quantitative PCR in blood is a reliable alternative to bone marrow cytogenetics

1 reference

https://api.crossref.org/works/10.1016%2FS1368-7646%2803%2900062-1

7 January 2021

High frequency of point mutations clustered within the adenosine triphosphate-binding region of BCR/ABL in patients with chronic myeloid leukemia or Ph-positive acute lymphoblastic leukemia who develop imatinib (STI571) resistance

1 reference

https://api.crossref.org/works/10.1016%2FS1368-7646%2803%2900062-1

7 January 2021

Detection of BCR-ABL mutations in patients with CML treated with imatinib is virtually always accompanied by clinical resistance, and mutations in the ATP phosphate-binding loop (P-loop) are associated with a poor prognosis

1 reference

https://api.crossref.org/works/10.1016%2FS1368-7646%2803%2900062-1

7 January 2021

BCR/ABL amplification in chronic myelocytic leukemia blast crisis following imatinib mesylate administration

1 reference

https://api.crossref.org/works/10.1016%2FS1368-7646%2803%2900062-1

7 January 2021

Several Bcr-Abl kinase domain mutants associated with imatinib mesylate resistance remain sensitive to imatinib

1 reference

https://api.crossref.org/works/10.1016%2FS1368-7646%2803%2900062-1

7 January 2021

Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors

1 reference

https://api.crossref.org/works/10.1016%2FS1368-7646%2803%2900062-1

7 January 2021

BCR-ABL independence and LYN kinase overexpression in chronic myelogenous leukemia cells selected for resistance to STI571.

1 reference

https://api.crossref.org/works/10.1016%2FS1368-7646%2803%2900062-1

7 January 2021

Effects of a selective inhibitor of the Abl tyrosine kinase on the growth of Bcr-Abl positive cells

1 reference

https://api.crossref.org/works/10.1016%2FS1368-7646%2803%2900062-1

7 January 2021

Role of alpha1 acid glycoprotein in the in vivo resistance of human BCR-ABL(+) leukemic cells to the abl inhibitor STI571

1 reference

https://api.crossref.org/works/10.1016%2FS1368-7646%2803%2900062-1

7 January 2021

Clinical resistance to STI-571 cancer therapy caused by BCR-ABL gene mutation or amplification

1 reference

https://api.crossref.org/works/10.1016%2FS1368-7646%2803%2900062-1

7 January 2021

BCR-ABL point mutants isolated from patients with imatinib mesylate-resistant chronic myeloid leukemia remain sensitive to inhibitors of the BCR-ABL chaperone heat shock protein 90.

1 reference

https://api.crossref.org/works/10.1016%2FS1368-7646%2803%2900062-1

7 January 2021

PDGFRA activating mutations in gastrointestinal stromal tumors.

1 reference

https://api.crossref.org/works/10.1016%2FS1368-7646%2803%2900062-1

7 January 2021

Molecular and chromosomal mechanisms of resistance to imatinib (STI571) therapy

1 reference

https://api.crossref.org/works/10.1016%2FS1368-7646%2803%2900062-1

7 January 2021

Targeted therapies in the treatment of Philadelphia chromosome-positive acute lymphoblastic leukemia

1 reference

https://api.crossref.org/works/10.1016%2FS1368-7646%2803%2900062-1

7 January 2021

Ph(+) acute lymphoblastic leukemia resistant to the tyrosine kinase inhibitor STI571 has a unique BCR-ABL gene mutation

1 reference

https://api.crossref.org/works/10.1016%2FS1368-7646%2803%2900062-1

7 January 2021

Presence of the BCR-ABL mutation Glu255Lys prior to STI571 (imatinib) treatment in patients with Ph+ acute lymphoblastic leukemia

1 reference

https://api.crossref.org/works/10.1016%2FS1368-7646%2803%2900062-1

7 January 2021

Overcoming STI571 resistance with the farnesyl transferase inhibitor SCH66336.

1 reference

https://api.crossref.org/works/10.1016%2FS1368-7646%2803%2900062-1

7 January 2021

Alpha1-acid glycoprotein expressed in the plasma of chronic myeloid leukemia patients does not mediate significant in vitro resistance to STI571.

1 reference

https://api.crossref.org/works/10.1016%2FS1368-7646%2803%2900062-1

7 January 2021

Hematologic and cytogenetic responses to imatinib mesylate in chronic myelogenous leukemia

1 reference

https://api.crossref.org/works/10.1016%2FS1368-7646%2803%2900062-1

7 January 2021

Dose escalation of imatinib mesylate can overcome resistance to standard-dose therapy in patients with chronic myelogenous leukemia

1 reference

https://api.crossref.org/works/10.1016%2FS1368-7646%2803%2900062-1

7 January 2021

Phosphatidylinositol-3 kinase inhibitors enhance the anti-leukemia effect of STI571.

1 reference

https://api.crossref.org/works/10.1016%2FS1368-7646%2803%2900062-1

7 January 2021

Preexistence and evolution of imatinib mesylate-resistant clones in chronic myelogenous leukemia detected by a PNA-based PCR clamping technique

1 reference

https://api.crossref.org/works/10.1016%2FS1368-7646%2803%2900062-1

7 January 2021

Mechanisms of resistance to imatinib (STI571) and prospects for combination with conventional chemotherapeutic agents

1 reference

https://api.crossref.org/works/10.1016%2FS1368-7646%2803%2900062-1

7 January 2021

In vitro studies of the combination of imatinib mesylate (Gleevec) and arsenic trioxide (Trisenox) in chronic myelogenous leukemia

1 reference

https://api.crossref.org/works/10.1016%2FS1368-7646%2803%2900062-1

7 January 2021

Determination of alpha-1 acid glycoprotein in patients with Ph+ chronic myeloid leukemia during the first 13 weeks of therapy with STI571.

1 reference

https://api.crossref.org/works/10.1016%2FS1368-7646%2803%2900062-1

7 January 2021

Spontaneous reversion from blast to chronic phase after withdrawal of imatinib mesylate in a patient with chronic myelogenous leukemia

1 reference

https://api.crossref.org/works/10.1016%2FS1368-7646%2803%2900062-1

7 January 2021

The c-KIT mutation causing human mastocytosis is resistant to STI571 and other KIT kinase inhibitors; kinases with enzymatic site mutations show different inhibitor sensitivity profiles than wild-type kinases and those with regulatory-type mutations

1 reference

https://api.crossref.org/works/10.1016%2FS1368-7646%2803%2900062-1

7 January 2021

MDR1 gene overexpression confers resistance to imatinib mesylate in leukemia cell line models

1 reference

https://api.crossref.org/works/10.1016%2FS1368-7646%2803%2900062-1

7 January 2021

Double minutes containing amplified bcr-abl fusion gene in a case of chronic myeloid leukemia treated by imatinib

1 reference

https://api.crossref.org/works/10.1016%2FS1368-7646%2803%2900062-1

7 January 2021

Effects of the Bcr/abl kinase inhibitors STI571 and adaphostin (NSC 680410) on chronic myelogenous leukemia cells in vitro

1 reference

https://api.crossref.org/works/10.1016%2FS1368-7646%2803%2900062-1

7 January 2021

Cotreatment with the histone deacetylase inhibitor suberoylanilide hydroxamic acid (SAHA) enhances imatinib-induced apoptosis of Bcr-Abl-positive human acute leukemia cells

1 reference

https://api.crossref.org/works/10.1016%2FS1368-7646%2803%2900062-1

7 January 2021

The impact of clonal evolution on response to imatinib mesylate (STI571) in accelerated phase CML.

1 reference

https://api.crossref.org/works/10.1016%2FS1368-7646%2803%2900062-1

7 January 2021

Analysis of Gene Expression Profiles in an Imatinib‐Resistant Cell Line, KCL22/SR

1 reference

https://api.crossref.org/works/10.1016%2FS1368-7646%2803%2900062-1

7 January 2021

A phase 2 study of imatinib in patients with relapsed or refractory Philadelphia chromosome-positive acute lymphoid leukemias

1 reference

https://api.crossref.org/works/10.1016%2FS1368-7646%2803%2900062-1

7 January 2021

Several types of mutations of the Abl gene can be found in chronic myeloid leukemia patients resistant to STI571, and they can pre-exist to the onset of treatment.

1 reference

https://api.crossref.org/works/10.1016%2FS1368-7646%2803%2900062-1

7 January 2021

Clinical resistance to the kinase inhibitor STI-571 in chronic myeloid leukemia by mutation of Tyr-253 in the Abl kinase domain P-loop

1 reference

https://api.crossref.org/works/10.1016%2FS1368-7646%2803%2900062-1

7 January 2021

Imatinib induces hematologic and cytogenetic responses in patients with chronic myelogenous leukemia in myeloid blast crisis: results of a phase II study.

1 reference

https://api.crossref.org/works/10.1016%2FS1368-7646%2803%2900062-1

7 January 2021

Structural mechanism for STI-571 inhibition of abelson tyrosine kinase

1 reference

https://api.crossref.org/works/10.1016%2FS1368-7646%2803%2900062-1

7 January 2021

Multiple BCR-ABL kinase domain mutations confer polyclonal resistance to the tyrosine kinase inhibitor imatinib (STI571) in chronic phase and blast crisis chronic myeloid leukemia

1 reference

https://api.crossref.org/works/10.1016%2FS1368-7646%2803%2900062-1

7 January 2021

Kinetics of BCR-ABL fusion transcript levels in chronic myeloid leukemia patients treated with STI571 measured by quantitative real-time polymerase chain reaction

1 reference

https://api.crossref.org/works/10.1016%2FS1368-7646%2803%2900062-1

7 January 2021

Comparison of effects of the tyrosine kinase inhibitors AG957, AG490, and STI571 on BCR-ABL--expressing cells, demonstrating synergy between AG490 and STI571.

1 reference

https://api.crossref.org/works/10.1016%2FS1368-7646%2803%2900062-1

7 January 2021

Restoration of sensitivity to STI571 in STI571-resistant chronic myeloid leukemia cells

1 reference

https://api.crossref.org/works/10.1016%2FS1368-7646%2803%2900062-1

7 January 2021

Drug responses of imatinib mesylate-resistant cells: synergism of imatinib with other chemotherapeutic drugs

1 reference

https://api.crossref.org/works/10.1016%2FS1368-7646%2803%2900062-1

7 January 2021

Effects of blocking platelet-derived growth factor-receptor signaling in a mouse model of experimental prostate cancer bone metastases

1 reference

https://api.crossref.org/works/10.1016%2FS1368-7646%2803%2900062-1

7 January 2021

Serial monitoring of BCR-ABL by peripheral blood real-time polymerase chain reaction predicts the marrow cytogenetic response to imatinib mesylate in chronic myeloid leukaemia

1 reference

https://api.crossref.org/works/10.1016%2FS1368-7646%2803%2900062-1

7 January 2021

Dual-specific Src and Abl kinase inhibitors, PP1 and CGP76030, inhibit growth and survival of cells expressing imatinib mesylate-resistant Bcr-Abl kinases

1 reference

https://api.crossref.org/works/10.1016%2FS1368-7646%2803%2900062-1

7 January 2021

Mechanisms of resistance imatinib (STI571) in preclinical models and in leukemia patients

1 reference

https://api.crossref.org/works/10.1016%2FS1368-7646%2803%2900062-1

7 January 2021

Inhibition of bcr-abl gene expression by small interfering RNA sensitizes for imatinib mesylate (STI571).

1 reference

https://api.crossref.org/works/10.1016%2FS1368-7646%2803%2900062-1

7 January 2021

10.1016/S1368-7646(03)00062-1

Identifiers

DOI

1 reference

release_xwiiup3x6bf2veiwerq2uo4uzq

9 August 2017

Fatcat ID

1 reference

Fatcat

https://api.fatcat.wiki/v0/release/xwiiup3x6bf2veiwerq2uo4uzq

24 November 2022

mapped directly with Wikidata item

1 reference